Main content

Freshfields advises Novartis on transaction with BioNTech

Freshfields Bruckhaus Deringer has advised the pharmaceutical company Novartis on the planned sale of Novartis Manufacturing GmbH, which operates a production plant for biotechnological substances in Marburg. Purchaser of the facility is the Mainz-based company BioNTech SE. BioNTech plans to produce the COVID-19 vaccine candidate BNT162 at the acquired plant pending regulatory approval. The plant would become BioNTech's largest production facility worldwide.

The transaction was negotiated in just a few weeks to allow BioNTech to start production at the facility as soon as possible. Subject to approval of relevant authorities, the transaction is expected to close in Q4 2020.

Freshfields has provided comprehensive advice to Novartis on all legal aspects of the divestiture, including service and support agreements for the seamless transfer of Novartis' production capacity to BioNTech.

The Freshfields team comprises Barbara Keil, Jacob Fontaine, Elisabeth Wulf and Panagiota Kavvada (all Corporate / M&A), David Beutel and Martin Rehberg (both Tax), Frank Röhling, Tobias Pukropski, Uwe Salaschek and Jonas von Kalben (all ACT and Foreign Trade Law) and Boris Dzida and Anne-Kathrin Bertke (both People & Reward). 

Media inquiries: Heiner Seidel, Senior Communications Lead Germany & Austria, E heiner.seidel@freshfields.com, T+49 69 27 30 84 25.

The Freshfields team was led by: